Evaluating the Anti-Tumor Activity of Lurbinectedin in the Treatment of Small Cell Lung Cancer, Which Has Progressed on or After Platinum-Based Chemotherapy

Video content above is prompted by the following:

1. Briefly describe the mechanism of action of lurbinectedin and how it might compare or contrast with other alkylating agents in the treatment of SCLC.
2. Please discuss your impressions of the antitumor activity of second-line lurbinectedin in 60 of the105 patients (57%) with relapsed SCLC and a CTFI interval of greater than 90 days after failure of a single, previous line of platinum-based therapy:
   1. To what degree does an ORR of 45%, a mDOR of 6.2-months, and a mOS of 11.2 months encourage the use of lurbinectedin in patients with CTFIs either less than or greater than 180 days?
   2. Given that only 20 patients formed the basis for this subgroup analysis, what additional studies should be conducted to confirm the sustained, antitumor efficacy of lurbinectedin among patients with relapsed SCLC who experience a protracted chemotherapy-free interval?
   3. What are the patient and/or disease factors that might motivate you to substitute lurbinectedin for chemotherapy in candidates eligible for platinum rechallenge?
   4. Is there a role for primary prophylaxis with G-CSFs in patients with relapsed SCLC?
3. In patients with SCLC who have relapsed after platinum-based chemotherapy, what do you consider to be a clinically meaningful DOR and progression-free survival that would resonate among community oncologists and encourage them to consider lurbinectedin as second-line therapy?